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Abstract
Background: ZnT3 is a membrane Zn2+ transporter that is responsible for concentrating Zn2+
into neuronal presynaptic vesicles. Zn2+ homeostasis in the brain is relevant to Alzheimer's disease
(AD) because Zn2+ released during neurotransmission may bind to Aβ peptides, accelerating the
assembly of Aβ into oligomers which have been shown to impair synaptic function.
Results: We quantified ZnT3 mRNA levels in Braak-staged human post mortem (pm) brain tissue
from medial temporal gyrus, superior occipital gyrus, superior parietal gyrus, superior frontal gyrus
and cerebellum from individuals with AD (n = 28), and matched controls (n = 5) using quantitative
real-time PCR. ZnT3 mRNA levels were significantly decreased in all four cortical regions examined
in the AD patients, to 45-60% of control levels. This reduction was already apparent at Braak stage
4 in most cortical regions examined. Quantification of neuronal and glial-specific markers in the
same samples (neuron-specific enolase, NSE; and glial fibrillary acidic protein, GFAP) indicated that
loss of cortical ZnT3 expression was more pronounced, and occurred prior to, significant loss of
NSE expression in the tissue. Significant increases in cortical GFAP expression were apparent as
the disease progressed. No gene expression changes were observed in the cerebellum, which is
relatively spared of AD neuropathology.
Conclusions: This first study to quantify ZnT3 mRNA levels in human pm brain tissue from
individuals with AD and controls has revealed a significant loss of ZnT3 expression in cortical
regions, suggesting that neuronal cells in particular show reduced expression of ZnT3 mRNA in
the disease. This suggests that altered neuronal Zn2+ handling may be an early event in AD
pathogenesis.
Background
ZnT3 is a Zn2+ transporter which is a member of the solute
carrier family 30 (SLC30), previously known as the cation
diffusion facilitator (CDF) family. Studies in mice have
shown that ZnT3 (SLC30A3) is primarily expressed in the
brain, particularly in the hippocampus, amygdala and cer-
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ebral cortex [1]. Within neurons, ZnT3 protein was
detected at membranes of small, round, clear synaptic ves-
icles from mossy fibre boutons in mouse and monkey
hippocampus [1,2]. ZnT3 is responsible for concentrating
Zn2+ into these vesicles [3], which is co-released with
glutamate upon depolarization [4,5]. Synaptic free Zn2+
levels can reach high concentrations during neurotrans-
mission (hundreds of μM) and its exact role at the synapse
is unclear, although it has been shown to modulate post-
synaptic events (both excitatory and inhibitory), probably
via effects on GABAA [6] and NMDA receptors [7-9].
Several findings indicate that Zn2+ homeostasis in the
brain is of relevance in Alzheimer's disease (AD). Aβ pep-
tides are found aggregated in amyloid plaques, one of the
characteristic hallmarks of AD neuropathology. Aβ binds
Zn2+ and this rapid interaction accelerates Aβ aggregation
on solid templates [10]. Current evidence indicates that
lower order, soluble, Aβ assemblies (known as oligomers)
are important in AD pathophysiology and that they
impair synaptic function [11]. Zn2+ released during neuro-
transmission was recently shown to play a key role in
mediating formation of these Aβ oligomers at synapses
[12]. Zn2+-induced Aβ aggregation can be prevented, and
even reversed, with chelating agents [13]. Treatment of a
transgenic mouse model relevant to AD (Tg2576) for
three months with the metal chelating agent DP-109
reduced the appearance of amyloid plaques and increased
soluble Aβ levels [14]. Crossing these animals with ZnT3
knock-out mice also resulted in reduced plaque load and
the animals displayed markedly less cerebral amyloid
angiopathy [15,16]. In patients with AD, Zn2+ levels have
been reported to be elevated in serum [17,18], and in
brain tissue [19-21], particularly associated with amyloid
plaques, cerebral amyloid angiopathy, and in cell bodies
and dendrites of neurofibrillary tangle-positive neurons
[22-24]. Compounds acting as metal ion chelators, such
as clioquinol and PBT2, have entered clinical trials for AD.
A slight improvement in clinical ratings was observed in
twenty AD patients after a three week treatment with clio-
quinol [25], and it reduced plasma Aβ42  levels and
increased Zn2+ levels in a phase two clinical trial in AD
[26].
These findings have prompted investigation of ZnT3 pro-
tein expression in the brains of another AD transgenic
mouse model (APPswe/PS1dE9) and in AD patients.
ZnT3 protein was abundantly detected in amyloid
plaques throughout the cortex and hippocampus as well
as amyloid angiopathic vessels in the APPswe/PS1dE9
mice, where levels were increased in comparison to wild-
type littermates [27]. ZnT3 also co-localized with amyloid
plaques throughout the cerebral cortex in five AD patients
and was detected in vessels with amyloid angiopathy [28],
although this study did not compare expression in control
human brain tissue.
The present study is the first to investigate ZnT3 mRNA
expression levels in human post mortem brains from indi-
viduals with AD, and matched controls. We used quanti-
tative real-time PCR (RT qPCR), a fast, straightforward
and reproducible technique which is increasingly becom-
ing the method of choice for profiling mRNA levels due to
its accuracy, wide dynamic range and sensitivity [29,30].
The accuracy of this technique is however totally depend-
ent on the use of valid reference genes for data normalisa-
tion. Traditionally, 'housekeeping genes' such as
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or
β-actin have been used for normalisation, but if expres-
sion of these genes is altered by the disease process, then
false negative or positive results may be obtained. It is
therefore essential that the expression stability of the ref-
erence gene(s) is examined and confirmed in the appro-
priate disease state and tissue prior to using the gene for
data normalisation. To identify a stable set of reference
genes, we examined the expression stability of a range of
candidate reference genes in post mortem brain samples
from individuals with AD, Parkinson's disease, dementia
with Lewy bodies, and controls [31]. The present study
used this validated set of reference genes to investigate
whether ZnT3 mRNA expression was altered in Braak-
staged post mortem brain tissue from individuals with
AD. Braak staging enabled the AD samples to be sub-
grouped according to progression of the neurofibrillary
tangle pathology [32]. We have also investigated the
expression of a glial marker (glial fibrillary acidic protein,
GFAP) and a neuronal marker (neuron-specific enolase,
NSE) to investigate whether any observed variations in
gene expression related to changing cell populations in
the tissues sampled. We analysed five brain regions,
affected to differing extents by AD neuropathology: cere-
bellum; medial temporal gyrus; superior occipital gyrus;
superior parietal gyrus; and superior frontal gyrus.
This study identified significant reductions in cortical
ZnT3 mRNA levels in AD, which occurred prior to overt
loss of NSE expression, indicating that impaired neuronal
Zn2+ handling may be an early event in AD pathogenesis.
Methods
Post-mortem brain tissue samples
Human post mortem brain tissue was obtained from The
Netherlands Brain Bank (Netherlands Institute for Neuro-
science, Amsterdam, Netherlands), in accordance with
local ethical approval, whereby autopsies on donors are
performed only when a written consent from the donor or
next of kin exists. The tissue originated from clinically well
documented and neuropathologically confirmed cases
and controls, with comprehensive information on ante-Molecular Neurodegeneration 2009, 4:53 http://www.molecularneurodegeneration.com/content/4/1/53
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and post-mortem (pm) factors. All tissue was Braak staged
[32]. Full details about the study subjects are presented in
Table 1. 28 AD patients were included (9 at Braak stage 4;
11 at Braak stage 5; 8 at Braak stage 6) and 5 matched con-
trols (4 at Braak stage 1; 1 at Braak stage 2). All individuals
in the AD group had a clinical diagnosis of dementia or
probable AD prior to death, and the neuropathological
diagnosis was either AD, or AD/Lewy body variant (AD/
LBV), as indicated on Table 1. The latter diagnosis was
applied to brains where some cortical LB were observed,
in addition to classical AD pathology. All controls also
underwent a full neuropathological evaluation to confirm
that they were not affected by AD or any other neurode-
generative disease. The tissue in this study was fresh-fro-
zen after a generally short post-mortem delay and all
tissue handling was done on dry ice to avoid thawing,
which would lead to increased RNA degradation [33]. As
shown in Table 1, there were no significant differences
between the study groups in terms of post-mortem delay,
previously reported to have a limited negative effect on
brain mRNA levels [34]; or CSF pH, shown to have a
major influence on brain mRNA levels [35,36]. Mean
brain weight was significantly lower in the AD group,
reflecting the brain atrophy caused by the disease. Frozen
tissue blocks were obtained from cerebellum and four cor-
tical gyri (medial temporal, superior occipital, superior
Table 1: Information about the study subjects
Diagnosis Gender Age Braak stage pm delay (min) CSF pH Brain weight (g)
control F 69 1 375 6.59 1264
control F 72 1 405 6.52 1296
control M 79 1 320 6.72 1322
control M 83 1 275 6.49 1422
control F 88 2 340 n.d. 1152
Control mean 3F/2 M 78.2 1.2 343 6.58 1291
AD F 84 4 230 6.64 1196
AD F 85 4 220 6.59 1065
AD F 93 4 335 6.65 1194
AD F 84 4 230 6.64 1196
AD F 87 4 240 6.91 955
AD F 101 4 265 6.93 1016
AD M 91 4 250 n.d. 1160
AD/LBV F 81 4 193 6.54 1096
AD/LBV F 76 4 295 6.78 1180
AD M 67 5 260 6.62 1094
AD F 77 5 252 6.43 1151
AD F 77 5 215 6.67 1235
AD M 86 5 335 6.39 1315
AD M 95 5 185 6.4 1203
AD M 70 5 525 6.25 1220
AD/LBV M 80 5 1670 6.19 1170
AD/LBV F 69 5 295 6.59 1039
AD/LBV F 84 5 365 6.1 1116
AD/LBV F 87 5 260 6.17 1022
AD/LBV M 84 5 275 6.54 1373
AD M 58 6 385 6.42 1273
AD F 87 6 300 6.66 852
AD F 87 6 250 6.9 1047
AD F 77 6 285 6.74 1116
AD F 91 6 275 6.55 949
AD F 66 6 215 6.42 1105
AD/LBV M 54 6 610 6.51 1334
AD/LBV F 69 6 295 6.41 1003
AD mean 19 F/9 M 80.3 5 340 6.54 1131
There were no statistically significant differences in age, cerebrospinal fluid (CSF) pH or pm delay between AD patients (Braak stages 4, 5 and 6) and 
controls (Braak stage 1 and 2). Brain weight was significantly lower in the AD patients, compared to controls (p = 0.01, unpaired t-test).Molecular Neurodegeneration 2009, 4:53 http://www.molecularneurodegeneration.com/content/4/1/53
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parietal and superior frontal) of each individual and
stored at -80°C.
Extraction of total RNA and cDNA synthesis
Tissue samples of approximately 100 mg were cut from
fresh-frozen post-mortem brain tissue blocks on dry ice,
and incubated with QIAzol lysis reagent (Qiagen). Sam-
ples were homogenised using a TissueLyser (Qiagen) and
total RNA was extracted using the RNeasy® lipid tissue
mini kit (Qiagen). To study RNA integrity, total RNA prep-
arations from cerebellum and medial temporal gyrus of
six AD patients and five controls were analysed using an
Agilent 2100 Bioanalyzer (Agilent Technologies) in a pre-
vious study in our laboratory (described in full by [31]). 2
μl of total RNA from each sample were used for spectro-
photometric quantitation using NanoDrop®  ND-1000
(NanoDrop®). 2 μg RNA were reverse transcribed using
the Omniscript® reverse transcription kit (Qiagen) accord-
ing to the manufacturer's protocol, in 20 μl reactions con-
taining 0.5 μM oligo-dT and 5 μM random nonomer
primers (Operon).
Real-time PCR
qPCR reactions were carried out with cDNA-specific Taq-
Man® gene expression assays using an ABI 7900HT real-
time PCR system (Applied Biosystems). Further informa-
tion about the gene expression assays is presented in Table
2. Each reaction contained 2 μl cDNA (corresponding to
20 ng reverse transcribed RNA), 0.25 μl TaqMan® gene
expression assay for the relevant gene, 2.5 μl TaqMan® uni-
versal PCR master mix (Applied Biosystems) and 0.25 μl
RNAse free water in a total volume of 5 μl. Sealed 384 well
plates were subjected to the following thermal cycling
conditions: 95°C for 10 min, followed by 40 cycles of
95°C for 15 sec and 60°C for 1 min. The reactions were
performed in triplicate and each qPCR run contained a
non-template (negative) control and two inter-run cali-
brators.
PCR Efficiency
A pool of cDNAs prepared from four different brain
regions of seven AD patients and two controls was used to
generate PCR efficiency curves. 10-fold serial dilutions of
the cDNA pool, ranging from ×1 dilution to ×1000000,
were used in quadruplicate qPCR reactions, carried out as
described above. Mean cycle threshold (Ct) values for
each cDNA dilution were plotted against the log10 of the
cDNA input, generating an efficiency plot (Figure 1).
Reaction efficiency (E) for each assay was calculated using
the slope of this line in the following equation: E = 10(-1/
slope) -1.
Data Analysis
Raw Ct values generated by the TaqMan® gene expression
assays were imported into the qBase Plus (Biogazelle)
software [15]. The qBase Plus algorithm enables normali-
sation to more than one reference gene and is able to take
into account gene-specific E, which distinguishes it from
the ΔΔCt method [37]. In addition, it also employs the sig-
nals from the inter-run calibrators to minimize run-to-run
variation [38]. In this study, ubiquitin C (UBC), succinate
dehydrogenase complex-subunit A (SDHA) and beta-2-
microglobulin (B2M) were analysed as potential reference
genes, as their expression levels were demonstrated to be
sufficiently stable in human pm brain tissue affected by
neurodegenerative disease in our previous study [31].
During the data normalisation process in qBase Plus it
was clear that reference gene stability decreased consider-
ably when B2M was included. We therefore used UBC and
SDHA to normalise the ZnT3 data presented.
Statistics
Statistical analysis was performed using GraphPad Prism
version 4.00 or InStat version 3.05 for Windows; Graph-
Pad Software, San Diego California USA, http://
www.graphpad.com. Non-parametric statistical tests were
used where data were not normally distributed, or where
there were significant differences between group standard
deviations.
Results
PCR efficiency
A pool of cDNA from four brain regions of AD patients
and controls was generated and 10-fold serial dilutions
assayed in order to determine PCR reaction efficiency
from the slope of the log10 cDNA vs Ct plot. PCR reaction
efficiency for the ZnT3 gene expression assay was 85%
(Figure 1). ZnT3 gene expression was normalised using
the two reference genes UBC and SDHA, whose efficien-
cies were previously determined to be 99% and 95%,
respectively, in a separate study using the same cDNA
pool in our laboratory [31]. The efficiency plots for all
three TaqMan® gene expression assays had r2 values of ≥
0.996.
Table 2: TaqMan® assay identification (ID) numbers, amplicon length and probe binding sequence
Gene name Assay ID Probe Binding Sequence (5'-3') Amplicon length
ZnT3 Hs00185728_m1 CAC CTG GCC ATC GAC TCC ACC GCT G 93
SDHA Hs00417200_m1 CGC CGC CGT GGT CGA GCT AGA AAA T 124
UBC Hs00824723_m1 GTG ATC GTC ACT TGA CAA TGC AGA T 71
B2 M Hs99999907_m1 TTA AGT GGG ATC GAG ACA TGT AAG C 75Molecular Neurodegeneration 2009, 4:53 http://www.molecularneurodegeneration.com/content/4/1/53
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ZnT3 expression in pm brain tissue
We analysed the gene expression level of ZnT3 in 28 AD
patients and 5 age-matched controls (Table 1). Compari-
son of all AD patients (Braak 4, 5 and 6) with all controls
(Braak 1 and 2) showed that ZnT3 expression was signifi-
cantly decreased in all four cortical regions examined in
the AD patients, compared to controls. ZnT3 mRNA levels
were reduced by 60% in the medial temporal gyrus (p =
0.0002, unpaired t-test); 52% in superior occipital gyrus
(p < 0.0001, unpaired t-test); 48% in superior frontal
gyrus (p = 0.002, unpaired t-test) and by 45% in the supe-
rior parietal gyrus (p = 0.009, Mann-Whitney). In the cer-
ebellum, ZnT3 expression level was extremely low (less
than 1% of the cortical expression levels in control sam-
ples) and no significant differences were detectable
between the study groups (20% lower in AD group, p =
0.55, unpaired t-test). Figure 2 presents these data in more
detail, sub-grouped according to Braak stage. The statisti-
cally significant reductions in ZnT3 expression level were
already present by Braak stage 4 in all cortical regions
examined, except for the superior parietal gyrus where the
reduction did not reach significance until Braak stage 5
(one-way ANOVA and Tukey-Kramer multiple compari-
sons test).
Expression of neuronal and glial-specific genes in pm brain 
tissue
We determined the mRNA expression levels of NSE, as a
neuronal-specific marker, and GFAP, as a glial-specific
marker, in these pm brain tissue samples in a separate
study (unpublished data). This identified significant
changes in expression of these genes as the disease pro-
gressed (as indicated by Braak stage). NSE expression was
negatively correlated with Braak stage (Spearman correla-
tion, p < 0.05) in medial temporal gyrus and superior
parietal gyrus, indicating significant loss of neuronal gene
expression in these regions as the disease progressed. This
correlation just failed to reach statistical significance in
the superior frontal gyrus (Spearman correlation, p =
0.056). Pooling of all AD patients (Braak 4, 5 and 6), for
comparison with all controls (Braak 1 and 2), showed that
NSE expression was significantly decreased in superior
frontal gyrus in AD (44% reduction), while the decreases
in NSE mRNA levels in superior parietal gyrus (27%
reduction), superior occipital gyrus (17% reduction) and
medial temporal gyrus (9% reduction) did not reach sta-
tistical significance. Kruskall-Wallis comparison of NSE
mRNA levels in the individual Braak goups 4, 5, or 6 ver-
sus controls (Braak 1 and 2), did not reveal any statisti-
cally significant changes.
In contrast, GFAP expression showed significant positive
correlations with Braak stage in medial temporal gyrus,
superior occipital gyrus, superior parietal gyrus and supe-
rior frontal gyrus (Spearman correlation, p < 0.05), indi-
cating significant gliosis as the disease progressed. Pooling
of all AD patients (Braak 4, 5 and 6), for comparison with
all controls (Braak 1 and 2), showed that GFAP expression
was significantly increased in medial temporal gyrus
affected by AD (to 364% of control, p = 0.01 Mann-Whit-
ney); in superior occipital gyrus (391% of control, p =
0.01 Mann-Whitney); and superior frontal gyrus (330%
of control, p = 0.04 Mann-Whitney); but this increase just
failed to achieve statistical significance in superior parietal
gyrus (173% of control, p = 0.09 Mann-Whitney).
Kruskall-Wallis comparison of GFAP mRNA levels in the
individual Braak goups 4, 5, or 6 versus controls (Braak 1
and 2), showed statistically significant increases at Braak
stage 6 in medial temporal gyrus, superior occipital gyrus
and superior parietal gyrus.
Notably, no statistically significant changes in NSE or
GFAP expression were present in the cerebellum, a region
which is relatively spared of AD-related neuropathology.
Ratio of ZnT3 expression to neuronal and glial-specific 
gene expression
The methodology employed in this study did not allow
visualisation of the cellular source of the ZnT3 mRNA
detected. As a first step towards exploring whether the
changes we observed in ZnT3 mRNA expression were
linked to the changing cell populations in the AD cortical
tissue, we calculated the ratio of ZnT3 expression (CNRQ)
to NSE, and to GFAP CNRQs for each individual and
brain region. We reasoned that if ZnT3 expression was
purely neuronal, then the ZnT3/NSE ratio in each individ-
ZnT3 efficiency plot Figure 1
ZnT3 efficiency plot. Quadruplicate ZnT3 qPCR analyses 
were carried out using the indicated dilutions of a cDNA 
pool, derived as described in the Methods section. Mean Ct 
values ± SD are presented for each dilution where the assay 
signal rose above the detection threshold. PCR reaction effi-
ciency for the ZnT3 TaqMan assay (85%) was calculated from 
the slope of the line as described in the Methods section.
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ual sample would be predicted to remain constant over
the course of the disease (as indicated by Braak stage).
In Figure 3 (a, b, c, d, e), it can be seen that there was a
decrease in the ZnT3 CNRQ/NSE CNRQ ratio in the supe-
rior occipital gyrus as the disease progressed which
achieved borderline statistical significance, but no signifi-
cant correlations between this ratio and Braak stage in any
of the other brain regions investigated. There was however
a consistent negative correlation between the ZnT3
CNRQ/GFAP CNRQ and Braak stage which was statisti-
cally significant in the medial temporal gyrus, superior
parietal gyrus and superior occipital gyrus, and was close
to statistical significance in the superior frontal gyrus (Fig-
ure 3f, g, h, i, j). These findings appear to confirm that
ZnT3 expression was predominantly neuronal, since the
ratio between ZnT3 and NSE expression remained rela-
tively constant, despite the significant losses in NSE
expression observed as the disease progressed in cortical
regions. In addition, the increased levels of GFAP were not
accompanied by increased levels of ZnT3 (negative corre-
lation), indicating that ZnT3 may not be expressed by glial
cells.
In the cerebellum, neither ratio showed any significant
correlation with Braak stage.
Discussion
This study identified a significant loss of ZnT3 mRNA
expression in four cortical regions in AD which occurred
early in the course of the disease (Figure 2). The reduc-
tions in cortical ZnT3 gene expression, by 45-60%, were
already well-established at Braak stage 4, when neocorti-
cal regions are still relatively unaffected by AD-related
neurofibrillary tangle pathology and overt neuronal loss
[32]. To study this directly in our samples, we analysed
expression of a neuronal marker (NSE) in this Braak-
staged tissue, which revealed significantly reduced NSE
expression as the disease progressed, reflecting the loss of
neuronal cells found in the disease. At Braak stage 4, how-
ever, we detected no significant changes in NSE expression
in any cortical region. This indicates that the changes in
ZnT3 expression occurred before significant neuronal
losses had occurred. We provide indirect evidence that pm
brain ZnT3 expression was predominantly neuronal (Fig-
ure 3), although our methodological approach did not
allow direct identification of the cellular source of ZnT3
mRNA. The fact that the ZnT3/NSE ratio did not generally
correlate with Braak stage indicates that expression of
these two mRNAs was decreasing roughly in parallel, even
though the ZnT3 changes were apparent earlier than NSE
changes as discussed above. In addition, we identified
increased GFAP expression in the AD pm brain tissue (cor-
tical regions), reflecting the astrogliosis and astrocyte acti-
vation associated with the disease, as reported by others
[39,40]. However, the ZnT3/GFAP ratio showed a nega-
tive correlation with Braak stage, indicating that the gliosis
at later stages of the disease was not associated with
increased ZnT3 expression. This suggests that glia were not
a major source of the ZnT3 mRNA detected here. This is
consistent with what is already known about the localiza-
tion of ZnT3 protein, in neuronal presynaptic vesicle
membranes [1,2]. The very low expression level we
detected in the cerebellum was also consistent with previ-
ous reports in mice [1,3]. Taken together, the present
study suggests that cortical neuronal cells show reduced
expression of ZnT3 mRNA in brain tissue affected by AD,
before NSE expression is compromised. This suggests that
the loss of ZnT3 expression is not solely due to the ongo-
ing neuronal cell death in AD, although this undoubtedly
contributes to it at later stages. One potential explanation
for this finding is that whilst NSE is expressed in most
neurons, Znt3 expression is more localised, as has been
shown in mouse and monkey [2]. Hence, the loss of ZnT3
expression prior to loss of NSE could reflect differences in
susceptibility of ZnT3-expressing neurons to AD.
This is the first direct study of ZnT3 mRNA expression in
human pm brain affected by AD to our knowledge. There
has been one previous study of ZnT3 protein levels in pm
brain in AD, which detected ZnT3 in the vicinity of amy-
loid plaques and blood vessels with amyloid angiopathy
ZnT3 expression in AD and control brain tissue Figure 2
ZnT3 expression in AD and control brain tissue. RNA 
was isolated from the pm brain tissue regions indicated and 
reverse transcribed prior to qPCR analysis in triplicate, and 
data analysis using qBase Plus, as described in the Methods 
section. Columns represent the mean ZnT3 expression level 
(expressed as CNRQ) ± SEM for each Braak stage, and the 
numbers at the base of each column (n) indicate the number 
of individuals included in that analysis. Statistical analysis 
(one-way ANOVA and Tukey-Kramer multiple comparisons 
test) revealed significant differences between control ZnT3 
expression levels (Braak stages 1 and 2), and ZnT3 expres-
sion levels in the AD brain tissue (Braak stages 4, 5, and 6): * 
p < 0.05; ** p < 0.01; *** p < 0.001 compared to control 
ZnT3 expression in the same brain region.
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ZnT3/NSE and ZnT3/GFAP CNRQ in AD and control brain tissue Figure 3
ZnT3/NSE and ZnT3/GFAP CNRQ in AD and control brain tissue. ZnT3 mean CNRQ values were divided by either 
mean NSE CNRQ, or mean GFAP CNRQ, for the same sample. This produced the ratios, which are shown plotted against the 
relevant Braak stage for that sample. Spearman correlation coefficients (r) are displayed on each graph, alongside the relevant p 
value.
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[28], although no control subjects were studied. Increased
protein levels of other zinc transporters in the same fam-
ily, which move zinc across different membranes to ZnT3
(ZnT-1, ZnT-4 and ZnT-6), have been previously reported
in AD and mild cognitive impairment [41]. Our finding of
decreased ZnT3 mRNA expression in the disease is per-
haps unexpected, and would not have been predicted by
previous studies of ZnT3 expression in rodents. These
studies would tend to predict that increased ZnT3 mRNA
expression may be associated with AD, while decreased
expression may be protective. For example, ZnT3 gene
knock-out in an AD transgenic mouse model (Tg2576)
resulted in reduced plaque load and cerebral amyloid
angiopathy [15,16], and a study of another AD transgenic
mouse model (APPswe/PS1dE9) detected increased ZnT3
protein levels in comparison to wild-type littermates [27].
Previous work investigating regulation of ZnT3 expression
has demonstrated a role for estrogen. Ovariectomy raised
ZnT3 levels and hippocampal synaptic vesicle Zn2+ levels,
while estrogen replacement lowered these [42]. These
changes were attributed to estrogen-induced reductions in
expression of the delta subunit of trans-Golgi network
adaptor-like complex AP-3. Genetic ablation of the delta
subunit of AP-3 in mocha mice leads to reduced cortical
vesicular ZnT3 protein expression and Zn2+ levels [43].
Given that early menopause and low estrogen levels have
been linked to increased risk for AD, these findings sug-
gest that increased ZnT3 levels may be associated with AD.
However this area is not clear-cut and while human epide-
miological data suggest that hormone replacement ther-
apy (HRT) reduces AD risk, some experimental evidence
demonstrates that HRT can increase the incidence of
dementia [44]. Dietary omega-3 polyunsaturated fatty
acid has also been shown to regulate ZnT3 expression.
Rats supplied with an omega-3-deficient diet perinatally
had increased expression of ZnT3 and increased levels of
hippocampal Zn2+ in adulthood [45]. Taken together with
the reported decrease in this class of fatty acids in pm
brains from AD patients, this again predicts that increased
ZnT3 expression may be associated with AD [46]. How-
ever, one study of a mouse model of accelerated aging
(senescence-accelerated mouse prone 10, SAMP10) iden-
tified reduced ZnT3 expression as the mice aged. This was
associated with increased expression of GFAP and exces-
sive hippocampal glutamatergic excitotoxicity, with dete-
rioration of learning and memory in the mice [47]. This
corresponds more closely to the changes we observed in
the AD pm brain tissue, where ZnT3 expression was
decreased, and GFAP increased.
Conclusions
The present study indicates that ZnT3 mRNA levels are sig-
nificantly reduced in the cortex in AD. The finding that
this change occurs prior to overt loss of NSE expression
indicates that it may precede wide-spread neuronal cell
loss. The mechanism(s) underlying this change require
further investigation to determine whether loss of ZnT3
expression exacerbates the disease, or occurs as a protec-
tive mechanism to reduce synaptic Zn2+ levels in the face
of AD-related increases in brain Zn2+ levels. Either way,
this finding indicates that altered neuronal Zn2+ handling
may be an early event in AD pathogenesis.
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